CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 72 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04493502
NCT04493502Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa

Eli Lilly and Company·interventional·Posted Jul 30, 2020·Updated Apr 28, 2023

In Brief

A Phase 2 clinical trial evaluating Placebo and LY3041658 for Hidradenitis Suppurativa. Completed, enrolled 72 participants across 20 sites in 2 countries.

Detailed Summary

The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesAustralia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJul 30, 2020
Enrollment StartAug 26, 2020
Primary CompletionMar 15, 2022
Study CompletionOct 13, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.9 years ago

Interventions

Placebodrug

Administered IV

LY3041658drug

Administered IV